Cited by 225Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

Tsimikas, Sotirios, Witztum, Joseph L., Miller, Elizabeth R., Sasiela, William J., Szarek, Michael, Olsson, Anders G., Schwartz, Gregory G.·2004·Circulation

DOI 10.1161/01.cir.0000141728.23033.b5

Open this paper in CoChat — free account

Abstract

Background— Oxidized phospholipids (OxPL) are present within atherosclerotic plaques and bound by lipoprotein (a) [Lp(a)] in plasma. This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS). Methods and Results— OxLDL-E06 (OxPL content on apolipoprotein B-100 [apoB] detected by antibody E06), apoB-100 immune complexes (apoB-IC), OxLDL autoantibodies, and Lp(a) levels were measured in 2341 patients at baseline and after 16 weeks of treatment with atorvastatin 80 mg/d or placebo. The OxLDL-E06 and apoB-IC data are reported per apoB-100 particle (OxPL/apoB, IC/apoB) and as total levels on all apoB-100 particles (total apoB-OxPL and total apoB-IC [eg, OxPL/apoB or IC/apoB×apoB-100 levels]). Compared with baseline values, atorvastatin reduced apoB-100 (−33%), total apoB-OxPL (−29.7%), total apoB-IC IgG (−29.5%), and IgM (−25.7%) ( P <0.0001 for all), whereas no change or an increase was observed with placebo. When normalized per apoB-100, compared with placebo, atorvastatin increased OxPL/apoB (9.5% versus −3.9%, P <0.0001) and Lp(a) (8.8% versus −0.7%, ( P <0.0001). A strong correlation was noted between OxPL/apoB and Lp(a) ( R =0.85, P <0.0001), consistent with previous data that Lp(a) binds OxPL. Conclusions— After atorvastatin treatment, total OxPL on all apoB-100 particles was decreased. However, there was enrichment of OxPL on a smaller pool of apoB-100 particles, in parallel with similar increases in Lp(a), suggesting binding by Lp(a). These data support the hypothesis that atorvastatin promotes mobilization and clearance of proinflammatory OxPL, which may contribute to a reduction in ischemic events after ACS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000141728.23033.b5

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citation
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,274
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques
Crisby, M., Fredrikson, G. N., Shah, P. K., Yano, J., Zhu, J., & Nilsson, J. Å. (2001) · Circulation · doi:10.1161/01.cir.103.7.926 · Cited by 999
Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes
Ehara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 780
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL
Binder, C. J., Hörkkö, S., Dewan, A. K., Chang, M.-K., Kieu, E., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., & Silverman, G. J. (2003) · Nature Medicine · doi:10.1038/nm876 · Cited by 735
Self-citation
Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL
Navab, M., Ananthramaiah, G. M., Reddy, S. T., Lenten, B. J. V., Ansell, B. J., Fonarow, G. C., Vahabzadeh, K., Hama, S. Y., Hough, G., Kamranpour, N., et al. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400001-jlr200 · Cited by 703
Lipid Lowering by Diet Reduces Matrix Metalloproteinase Activity and Increases Collagen Content of Rabbit Atheroma
Aikawa, M., Aïkawa, E., Okada, Y., Voglic, S. J., Clinton, S. K., Brinckerhoff, C., Sukhova, G. K., & Libby, P. (1998) · Circulation · doi:10.1161/01.cir.97.24.2433 · Cited by 552
Single LDL Apheresis Improves Endothelium-Dependent Vasodilatation in Hypercholesterolemic Humans
Tamai, O., Matsuoka, H., Itabe, H., Wada, Y., Kohno, K., & Imaizumi, T. (1997) · Circulation · doi:10.1161/01.cir.95.1.76 · Cited by 543
Early Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival
Stenestrand, U. (2001) · JAMA · doi:10.1001/jama.285.4.430 · Cited by 531
Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability
Nishi, K., Itabe, H., Uno, M., Kitazato, K. T., Horiguchi, H., Shinno, K., & Nagahiro, S. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000033829.14012.18 · Cited by 409
High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study
Kinlay, S., Schwartz, G. G., OLSSON, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M. J., Libby, P., & Ganz, P. (2003) · Circulation · doi:10.1161/01.cir.0000091404.09558.af · Cited by 403
Self-citation
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes
Tsimikas, S., Bergmark, C., Beyer, R. W., Patel, R., Pattison, J., Miller, E. R., Juliano, J., & Witztum, J. L. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02769-9 · Cited by 348
Self-citation
Oral D-4F Causes Formation of Pre-β High-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S. Y., Hough, G., Grijalva, V. R., Wagner, A. C., Frank, J. S., Datta, G., Garber, D. W., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134275.90823.87 · Cited by 322
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Aronow, H. D., Topol, E. J., Roe, M. T., Houghtaling, P. L., Wolski, K. E., Lincoff, A. M., Harrington, R. A., Califf, R. M., Ohman, E. M., Kleiman, N. S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04257-4 · Cited by 308
Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
Aviram, M., Rosenblat, M., Bisgaier, C. L., & Newton, R. S. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00032-x · Cited by 291
Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a)
Tsimikas, S., Lau, H. K. F., Han, K., Shortal, B. P., Miller, E. R., Segev, A., Curtiss, L. K., Witztum, J. L., & Strauss, B. H. (2004) · Circulation · doi:10.1161/01.cir.0000130844.01174.55 · Cited by 285
Self-citation
Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery Atherosclerosis
Karvonen, J., Päivänsalo, M. J., Kesäniemi, Y. A., & Hörkkö, S. (2003) · Circulation · doi:10.1161/01.cir.0000092891.55157.a7 · Cited by 275
A Single Protease, Apg4B, Is Specific for the Autophagy-related Ubiquitin-like Proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L
Hemelaar, J., Lelyveld, V. S., Kessler, B. M., & Ploegh, H. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308762200 · Cited by 210
Lipid Lowering Reduces Oxidative Stress and Endothelial Cell Activation in Rabbit Atheroma
Aikawa, M., Sugiyama, S., Hill, C. C., Voglic, S. J., Aikawa, E. R., Fukumoto, Y., Schöen, F. J., Witztum, J. L., & Libby, P. (2002) · Circulation · doi:10.1161/01.cir.0000028465.52694.9b · Cited by 205
Self-citation
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
Dart, A. M., Jerums, G., Nicholson, G. C., dʼEmden, M. C., Hamilton‐Craig, I. R., Tallis, G. A., Best, J. D., West, M., SULLIVAN, D. R., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 186
Evidence for a Role of Phospholipid Oxidation Products in Atherogenesis
Berliner, J. A. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00098-6 · Cited by 182
Lipoprotein(a)
Hobbs, H. H., & White, A. L. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00005 · Cited by 178
Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms
Cannon, C. P., D, E. B. M., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200407000-00019 · Cited by 159
Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a)
Edelstein, C., Pfaffinger, D., Hinman, J., Miller, E. R., Lipkind, G. M., Tsimikas, S., Bergmark, C., Getz, G. S., Witztum, J. L., & Scanu, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310425200 · Cited by 137
Self-citation
Malondialdehyde-Modified LDL as a Marker of Acute Coronary Syndromes
Holvoet, P. (1999) · JAMA · doi:10.1001/jama.281.18.1718 · Cited by 126
In Vivo Uptake of Radiolabeled MDA2, an Oxidation-Specific Monoclonal Antibody, Provides an Accurate Measure of Atherosclerotic Lesions Rich in Oxidized LDL and Is Highly Sensitive to Their Regression
Tsimikas, S., Shortal, B. P., Witztum, J. L., & Palinski, W. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.3.689 · Cited by 123
Self-citation
Improvement of coronary vasodilatation capacity through single LDL apheresis
Mellwig, K. P., Baller, D., Gleichmann, U., Moll, D., Betker, S., Weise, R., & Notohamiprodjo, G. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00055-0 · Cited by 123
Autoantibodies to OxLDL Are Decreased in Individuals With Borderline Hypertension
Wu, R., Fairé, U. D., Lemne, C. E., Witztum, J. L., & Frostegård, J. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.53 · Cited by 120
Self-citation
Changes in Dietary Fat Intake Alter Plasma Levels of Oxidized Low-Density Lipoprotein and Lipoprotein(a)
Silaste, M.-L., Rantala, M., Alfthan, G., Aro, A., Witztum, J. L., Kesäniemi, Y. A., & Hörkkö, S. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000118012.64932.f4 · Cited by 119
Self-citation
Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F 2 -Isoprostane Formation in Hypercholesterolemic Subjects
Caterina, R. D., Cipollone, F., Filardo, F. P., Zimarino, M., Bernini, W., Lazzerini, G., Bucciarelli, T., Falco, A., Marchesani, P., Muraro, R., et al. (2002) · Circulation · doi:10.1161/01.cir.0000038500.43292.d7 · Cited by 113
Antibodies to Oxidized LDL in Relation to Intima-Media Thickness in Carotid and Femoral Arteries in 58-Year-Old Subjectively Clinically Healthy Men
Hulthe, J., Bokemark, L., & Fagerberg, B. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.1.101 · Cited by 105
Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects
Schaefer, E. J., McNamara, J. R., Tayler, T. D., Daly, J. A., Gleason, J. A., SEMAN, L. J., Ferrari, A., & Rubenstein, J. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02591-2 · Cited by 90
Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein
Penny, W. F., Ben‐Yehuda, O., Kuroe, K., Long, J., Bond, A., Bhargava, V., Peterson, J. F., McDaniel, M. B., Juliano, J., Witztum, J. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01180-3 · Cited by 82
Self-citation
A Randomized Trial of the Effects of Atorvastatin and Niacin in Patients with Combined Hyperlipidemia or Isolated Hypertriglyceridemia
McKenney, J. M., McCormick, L. S., Weiss, S. R., Koren, M. J., Kafonek, S. D., & Black, D. M. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00311-2 · Cited by 75
Lipoprotein(a): still an enigma?
Kostner, K., & Kostner, G. M. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200208000-00006 · Cited by 70
Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin
Slunga, L., Johnson, O., & Dahlén, G. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220611 · Cited by 42
Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects
Kobayashi, J., Katsube, S., Shimoda, M., Furuhashi, K., Kitano, S., Masuda, M., Maruyama, T., & Shinomiya, M. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(02)00103-1 · Cited by 27
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia
Bredie, S. J. H. (1996) · The Netherlands Journal of Medicine · doi:10.1016/0300-2977(96)00015-0 · Cited by 22
Statins and Oxidative Stress During Atherogenesis
Norata, G. D., Pirillo, A., & Catapano, A. L. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000071772.88247.14 · Cited by 18

Research works printed but not linked: 10

1994, Lancet, 344, 1383
10.1161/circ.97.24.2433 · DOI
10.1161/atvb.21.11.1712 · DOI
2003, J Cardiovasc Risk, 10, 181
10.1161/circ.103.15.1955 · DOI
10.1161/circ.95.1.76 · DOI
10.1161/atvb.20.3.689 · DOI
10.1161/circ.103.7.926 · DOI
10.1161/hyp.33.1.53 · DOI
10.1161/atvb.21.1.101 · DOI

Sorted by citations

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043175 · Cited by 782
Self-citation
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Self-citation
Statin therapy increases lipoprotein(a) levels
Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz310 · Cited by 512
Self-citation

See all 225

Authors: Tsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G.
Affiliations: Linköping University (SE)
Corresponding author: Tsimikas, Sotirios
ORCID: Tsimikas, Sotirios
Witztum, Joseph L.
Miller, Elizabeth R.
Sasiela, William J.
Szarek, Michael
Olsson, Anders G.
Schwartz, Gregory G.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-09-14
Volume: 110
Issue: 11
Pages: 1406-1412
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000141728.23033.b5
OpenAlex: W2109629533
Semantic Scholar: 5d8d1d7bcae3432d2e03d42643169af12f5e5419
Cited by: 225
References: 45
Citations by year: 2026: 2 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 15 · 2015: 13 · 2014: 10 · 2013: 10 · 2012: 9
FWCI: 14.84
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Donald W. Reynolds Foundation
Pfizer
National Heart, Lung, and Blood Institute (P50HL056989, HL-56989)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: atorvastatin, oxidized phospholipids, oxidized LDL, apolipoprotein B-100, immune complexes, lipoprotein(a), acute coronary syndrome, statin therapy, atherosclerosis, atherosclerotic plaque
MeSH terms: Atorvastatin, Aged, Angina, Unstable, Antigen-Antibody Complex, Apolipoproteins B, Autoantibodies, Double-Blind Method, Female, Heptanoic Acids, Humans, Immunoglobulin G, Immunoglobulin M, Lipoproteins, LDL, Male, Middle Aged, Myocardial Infarction, Oxidation-Reduction, Phospholipids, Pyrroles, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Apolipoprotein B-100

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks